EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022

Date: November 30, 2012
Pages: 69
Price:
US$ 3,995.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: E1F87D5DC89EN
Leaflet:

Download PDF Leaflet

EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022

Summary

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. Vaccination has been shown to reduce influenza morbidity and mortality and high economic burden associated with influenza illness. GlobalData’s epidemiologists expect seasonal influenza vaccination coverage rates for all countries but the UK and China to remain constant on average throughout the forecast period. Vaccine demand for all nine countries, on the other hand, is forecast to increase in the next decade. Overall, the US is projected to have the largest vaccine demand in the next decade at over 158 million, followed by Japan’s 37.4 million, whereas Spain is expected to have the lowest demand at just over eight million. Annual growth in vaccine demand for the next 10 years is highest in India (2.10%) and the UK (1.38%) and lowest in Japan (0.42%) and Germany (0.26%). By 2022, the US will have the highest vaccination coverage rate (46.1%) and India and China the lowest (both at 1.7%). Vaccine demand is expected to increase across all nine markets, even in countries where vaccination coverage rates remain stable. This increase is mostly due to population growth, especially growth in the elderly age group.

Scope
  • The Seasonal Influenza Vaccines EpiCast Report provides an overview of risk factors for seasonal influenza and global trends for seasonal influenza vaccination coverage.
  • Data provided for the US, France, Germany, Italy, Spain, the UK, Japan, India, and China.
  • It includes a 10-year epidemiological forecast of seasonal influenza vaccination coverage segmented by age (0–4 years, 5–64 years, and =65 years) in these nine markets.
Reasons to buy
  • This forecast is supported by at least 10 years of historical data sourced mostly from government reports and country-specific studies published by peer-reviewed journals.
  • A major strength of the analysis is the consideration of a comprehensive list of factors such as policy, historical and current events, such as the H1N1 pandemic, cultural perception, economic situations, and population growth in forecasting trends.
  • Forecast methodology is consistent across all nine markets, thereby allowing for a meaningful comparison of the nine markets.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 Catalyst
2.2 Upcoming Related Reports

3 EPIDEMIOLOGY

3.1 Risk Factors and Comorbidities
3.2 Global Trends
  3.2.1 United States
  3.2.2 France
  3.2.3 Germany
  3.2.4 Italy
  3.2.5 Spain
  3.2.6 United Kingdom
  3.2.7 Japan
  3.2.8 India
  3.2.9 China
3.3 Forecast Methodology
  3.3.1 Sources Used
  3.3.2 Forecast Assumptions and Methods
3.4 Epidemiological Forecast (2012–2022)
  3.4.1 Seasonal Influenza Vaccination Coverage, N (%)
3.5 Discussion
  3.5.1 Global Vaccination Coverage Outlook
  3.5.2 Limitations in Analysis
  3.5.3 Strengths of Analysis

4 APPENDIX

4.1 Bibliography
4.2 About the Authors
  4.2.1 Epidemiologists
  4.2.2 Reviewers
  4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
  4.2.4 Global Head of Healthcare
4.3 About GlobalData
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

LIST OF TABLES

Table 1: United States, Sources of Vaccination Coverage Data
Table 2: France, Sources of Vaccination Coverage Data
Table 3: Germany, Sources of Vaccination Coverage Data
Table 4: Italy, Sources of Vaccination Coverage Data, 2004–2006
Table 5: Italy, Sources of Vaccination Coverage Data, 2008–2012
Table 6: Spain, Sources of Vaccination Coverage Data
Table 7: United Kingdom, Sources of Vaccination Coverage Data
Table 8: Japan, Sources of Vaccination Coverage Data
Table 9: India and China, Sources of Vaccination Coverage Data
Table 10: Nine Markets, Seasonal Influenza Vaccination Coverage, N (%), 2012–2022

LIST OF FIGURES

Figure 1: United States, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 2: France, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 3: Germany, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 4: Italy, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 5: Spain, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 6: United Kingdom, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 7: Japan, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 8: India, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 9: China, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 10: Nine Markets, Seasonal Influenza Vaccination Coverage, N, 2012–2022

Ask Your Question

EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: